Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Ana Cecília LuccheseLuciana M SarinEduardo J Muniz MagalhãesLorena Catarina Del SantCamila B PuertasMarco A TuenaCarolina NakahiraVictor Ar FavaRodrigo DelfinoJuliana SurjanMatheus S SteiglichMatheus Ghossain BarbosaGuilherme AbdoFrederico Molina CohrsAroldo LiberatoriJosé A Del PortoAcioly Lt LacerdaSérgio Baxter AndreoliPublished in: Journal of psychopharmacology (Oxford, England) (2021)
Our results suggest that higher levels of treatment resistance may be associated with a poor response to SC esketamine. Unlike traditional pharmacotherapies, it might benefit those with poor prognosis such as patients with depression and comorbid anxiety. Therefore, future research could investigate whether esketamine should receive a more prominent place in the treatment algorithm for TRD.